Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts.

With its Q1 2025 results on Wednesday, Novo Nordisk (NVO) lowered its full-year outlook, but its shares were rising in European trading after the pharma giant projected a sales recovery for its blockbuster weight loss therapy Wegovy in the months ahead.

Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving the way for a sales rebound later this year.